Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.09.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Evan W Kleinboehl und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455,…. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, Iduronidase, Mucopolysaccharidosis I, Glycosaminoglycans. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Enzymopathy disorders are the result of missing or defective enzymes. Among these enzymopathies, mucopolysaccharidosis type I is a rare genetic lysosomal storage disorder caused by mutations in the gene encoding alpha-L-iduronidase (IDUA), which ultimately causes toxic buildup of glycosaminoglycans (GAGs). There is currently no cure and standard treatments provide insufficient relief to the skeletal structure and central nervous system (CNS). Human memory T (Tm) cells migrate throughout the body's tissues and can persist for years, making them an attractive approach for cellular-based, systemic enzyme replacement therapy. Here, we tested genetically engineered, IDUA-expressing Tm cells as a cellular therapy in an immunodeficient mouse model of MPS I. Our results demonstrate that a single dose of engineered Tm cells leads to detectable IDUA enzyme levels in the blood for up to 22 weeks and reduced urinary GAG excretion. Furthermore, engineered Tm cells take up residence in nearly all tested tissues, producing IDUA and leading to metabolic correction of GAG levels in the heart, lung, liver, spleen, kidney, bone marrow, and the CNS, although only minimal improved cognition was observed. Our study indicates that genetically engineered Tm cells hold great promise as a platform for cellular-based enzyme replacement therapy for the treatment of mucopolysaccharidosis type I and potentially many other enzymopathies and protein deficiencies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Center for Genome Engineering, University of Minnesota, Minneapo…
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- NIH HHS
Zitieren
APA
Kleinboehl, E. W., Laoharawee, K., Jensen, J. D., Peterson, J. J., Slipek, N. J., Wick, B. J., Johnson, M. J., Webber, B. R., & Moriarity, B. S. (2024). Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.09.033
Vancouver
Kleinboehl EW, Laoharawee K, Jensen JD, Peterson JJ, Slipek NJ, Wick BJ, et al. Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.09.033
BibTeX
@article{Kleinboehl2024,
author = {Kleinboehl, Evan W and Laoharawee, Kanut and Jensen, Jacob D and Peterson, Joseph J and Slipek, Nicholas J and Wick, Bryce J and Johnson, Matthew J and Webber, Beau R and Moriarity, Branden S},
title = {Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.09.033}
}
EUVIMED